Source-grounded facts extracted from VitaNova Life Sciences Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
VitaNova Life Sciences Corp: Increase in authorized shares to 200,000,000 common and 10,000,000 preferred stock, via Certificate of Amendment filed November 12, 2025 (effective 2025-11-12).
“On November 12, 2025, the Company filed a Certificate of Amendment to the Articles of Incorporation (the “ Previous Certificate of Amendment ”), which became effective on that date, to increase the number of authorized shares of Common Stock and to authorize the issuance of blank check preferred stock”
VitaNova Life Sciences Corp: Name change to VitaNova Life Sciences Corporation and 1-for-3 reverse stock split, effected via Certificate of Amendment filed January 9, 2026 (effective 2026-01-09).
“On January 9, 2026, a Certificate of Amendment to the Articles of Incorporation (the “ Certificate of Amendment ”) effecting the Name Change was filed with the Secretary of State of the State of Nevada and became effective on that date.”
VitaNova Life Sciences Corp entered into Purchase Agreements with ten investors valued at aggregate gross proceeds of $957,051 (effective 2024-01-30).
“On January 30, 2024, Yijia Group Corp. (the “Company”) entered into ten securities purchase agreements (the “Purchase Agreements”) in connection with its private offering (the “Offering”) of the Company’s unregistered shares of common stock, par value $0.001, with a total of ten (10) investors, consisting of two (2) U.S. accredited investors, as defined under Rule 501 of Regulation D, and eight (8) non-U.S. investors (individually, an “Investor” and collectively, the “Investors”), at a purchase price of $0.05 per share.”
Dr. Steve Niu was appointed as CFO at VitaNova Life Sciences Corp.
“Effective as of January 8, 2024, the Board appointed Dr. Steve Niu as the CFO of the Company, until the next annual meeting of the Company’s stockholders, and until his successor is elected and qualified or until his prior death, resignation or removal.”
Qiuping Lu resigned as CFO at VitaNova Life Sciences Corp.
“Effective as of January 8, 2024, Qiuping Lu resigned from her position as the CFO of Yijia Group Corp (the “Company”).”
VitaNova Life Sciences Corp underwent a change of control involving Ms. Caihong Qu for $0 (closed 2023-09-12).
“Ms. Caihong Qu, Mr. Xianchang Ma's sole heir, was allocated 5,066,250 shares of the Company's common stock at a consideration of $0.”
Ruiming Zhou was appointed as Director at VitaNova Life Sciences Corp.
“On September 13, 2023, the majority shareholder inducted Ms. Qiuping Lu, and Mr. Ruiming Zhou to the Board.”
Qiuping Lu was appointed as Chief Executive Officer, President, Chief Financial Officer at VitaNova Life Sciences Corp.
“On September 13, 2023, the Board resolved to appoint Ms. Qiuping Lu as the Chief Executive Officer, President, Chief Financial Officer of the Company.”
Qiuping Lu was appointed as Director at VitaNova Life Sciences Corp.
“On September 13, 2023, the majority shareholder inducted Ms. Qiuping Lu, and Mr. Ruiming Zhou to the Board.”
Xianchang Ma departed as Chief Executive Officer, President, Chief Financial Officer and Director at VitaNova Life Sciences Corp.
“Mr. Xianchang Ma, previously the Chief Executive Officer, President, Chief Financial Officer and Director of the Company, passed away on August 3, 2023.”
VitaNova Life Sciences Corp underwent a change of control involving Xianchang Ma for $470,562 (closed 2023-06-14).
“of common stock of the Company to Mr. Ma, constituting approximately 86.3% of the issued and outstanding shares of the Company as of May 2, 2023, for a total consideration of $470,562, derived from the purchaser’s personal funds. The Securities Purchase Agreement was closed on June 14, 2023. Following the closing, Mr. Ma acquired a beneficial interest in”
Xianchang Ma was appointed as Director at VitaNova Life Sciences Corp.
“On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.”
Xianchang Ma was appointed as Chief Financial Officer at VitaNova Life Sciences Corp.
“On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.”
Xianchang Ma was appointed as President at VitaNova Life Sciences Corp.
“On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.”
Xianchang Ma was appointed as Chief Executive Officer at VitaNova Life Sciences Corp.
“On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.”
Barry Sytner resigned as Director at VitaNova Life Sciences Corp.
“On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.”
Barry Sytner resigned as Chief Financial Officer at VitaNova Life Sciences Corp.
“On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.”
Barry Sytner resigned as President at VitaNova Life Sciences Corp.
“On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.”
Barry Sytner resigned as Chief Executive Officer at VitaNova Life Sciences Corp.
“On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.”
Barry Sytner was appointed as Chief Executive Officer and Director at VitaNova Life Sciences Corp.
“On July 28, 2021, Barry Sytner, age 68, was appointed as Chief Executive Officer and Director of the registrant.”
Jian Yang resigned as officer and director at VitaNova Life Sciences Corp.
“On July 28, 2021, Shaoyin Wu, Kim Lee Poh and Jian Yang resigned as officers and directors of the registrant.”
Kim Lee Poh resigned as officer and director at VitaNova Life Sciences Corp.
“On July 28, 2021, Shaoyin Wu, Kim Lee Poh and Jian Yang resigned as officers and directors of the registrant.”
Shaoyin Wu resigned as officer and director at VitaNova Life Sciences Corp.
“On July 28, 2021, Shaoyin Wu, Kim Lee Poh and Jian Yang resigned as officers and directors of the registrant.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.